Alphatec Holdings, Inc. Income Taxes Disclosure
10. Income Taxes
The components of the pretax loss are presented in the following table (in thousands):
|
|
Year Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
U.S. Domestic |
|
$ |
(140,449 |
) |
|
$ |
(147,954 |
) |
|
$ |
(178,313 |
) |
Foreign |
|
|
(2,954 |
) |
|
|
(14,119 |
) |
|
|
(8,602 |
) |
Net loss before taxes |
|
$ |
(143,403 |
) |
|
$ |
(162,073 |
) |
|
$ |
(186,915 |
) |
The components of the provision for income taxes are presented in the following table (in thousands):
|
|
Year Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Current income tax provision: |
|
|
|
|
|
|
|
|
|
|||
Federal |
|
$ |
(389 |
) |
|
$ |
78 |
|
|
$ |
76 |
|
State |
|
|
506 |
|
|
|
349 |
|
|
|
332 |
|
Foreign |
|
|
426 |
|
|
|
209 |
|
|
|
145 |
|
Total current |
|
|
543 |
|
|
|
636 |
|
|
|
553 |
|
Deferred income tax provision: |
|
|
|
|
|
|
|
|
|
|||
Federal |
|
|
48 |
|
|
|
44 |
|
|
|
37 |
|
State |
|
|
— |
|
|
|
(8 |
) |
|
|
— |
|
Foreign |
|
|
(636 |
) |
|
|
(622 |
) |
|
|
(867 |
) |
Total deferred |
|
|
(588 |
) |
|
|
(586 |
) |
|
|
(830 |
) |
Total income tax provision |
|
$ |
(45 |
) |
|
$ |
50 |
|
|
$ |
(277 |
) |
The reconciliation of the U.S. federal statutory income tax rate to the Company’s effective tax rate for the year ended December 31, 2025 after the adoption of ASU 2023-09 is as follows (in thousands):
|
|
|
|
|||||
|
|
2025 |
|
|||||
|
|
$ |
|
|
% |
|
||
U.S. federal statutory income tax rate |
|
$ |
(30,115 |
) |
|
|
21.00 |
% |
, net of federal income tax effect (1) |
|
|
(775 |
) |
|
|
0.54 |
|
Foreign tax effects |
|
|
|
|
|
|
||
France |
|
|
|
|
|
|
||
Changes in valuation allowances |
|
|
(1,684 |
) |
|
|
1.18 |
|
Other |
|
|
1,387 |
|
|
|
(0.97 |
) |
Other foreign jurisdictions |
|
|
708 |
|
|
|
(0.49 |
) |
Tax credits |
|
|
|
|
|
|
||
Research and development credits |
|
|
(3,423 |
) |
|
|
2.39 |
|
Changes in valuation allowances |
|
|
23,958 |
|
|
|
(16.71 |
) |
Nontaxable or nondeductible items |
|
|
|
|
|
|
||
Stock-based compensation |
|
|
4,742 |
|
|
|
(3.31 |
) |
Repurchase premium |
|
|
3,198 |
|
|
|
(2.23 |
) |
Other |
|
|
353 |
|
|
|
(0.25 |
) |
Changes in unrecognized tax benefits |
|
|
2,619 |
|
|
|
(1.83 |
) |
Other adjustments |
|
|
(1,013 |
) |
|
|
0.71 |
|
Effective income tax and tax rate |
|
$ |
(45 |
) |
|
|
0.03 |
% |
(1) State taxes in California and Texas made up the majority (greater than 50%) of the tax effect in this category.
The reconciliation of the U.S. federal statutory income tax rate to the Company’s effective tax rate for the years ended December 31, 2024 and 2023, prior to the adoption of ASU 2023-09, is as follows:
|
|
|
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Federal statutory rate |
|
|
21.00 |
% |
|
|
21.00 |
% |
Adjustments for tax effects of: |
|
|
|
|
|
|
||
State taxes, net |
|
|
(0.17 |
) |
|
|
(0.13 |
) |
Stock-based compensation |
|
|
(3.57 |
) |
|
|
(1.12 |
) |
Rate differential |
|
|
0.32 |
|
|
|
0.18 |
|
Foreign taxes |
|
|
(0.02 |
) |
|
|
(0.07 |
) |
Other permanent adjustments |
|
|
(0.71 |
) |
|
|
(0.21 |
) |
Credits |
|
|
2.06 |
|
|
|
1.53 |
|
Federal uncertain tax positions |
|
|
(1.14 |
) |
|
|
(1.50 |
) |
Expiration of tax attribute |
|
|
(0.11 |
) |
|
|
(0.09 |
) |
Other |
|
|
0.55 |
|
|
|
0.70 |
|
Valuation allowance |
|
|
(18.23 |
) |
|
|
(20.12 |
) |
Effective income tax rate |
|
|
(0.02 |
)% |
|
|
0.17 |
% |
Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2025 and 2024 are as follows (in thousands):
|
|
December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Deferred tax assets: |
|
|
|
|
|
|
||
Net operating losses |
|
$ |
205,074 |
|
|
$ |
176,352 |
|
Interest |
|
|
24,546 |
|
|
|
21,439 |
|
Capitalized research and development expenses |
|
|
21,551 |
|
|
|
35,177 |
|
Inventory |
|
|
18,750 |
|
|
|
16,183 |
|
Lease liability |
|
|
7,648 |
|
|
|
8,388 |
|
Stock-based compensation |
|
|
16,656 |
|
|
|
16,754 |
|
Accruals and reserves |
|
|
9,817 |
|
|
|
7,277 |
|
Legal settlement |
|
|
1,656 |
|
|
|
341 |
|
Income tax credit carryforwards |
|
|
10,319 |
|
|
|
7,554 |
|
Total deferred tax assets |
|
|
316,017 |
|
|
|
289,465 |
|
Valuation allowance |
|
|
(246,371 |
) |
|
|
(246,744 |
) |
Total deferred tax assets, net of valuation allowance |
|
|
69,646 |
|
|
|
42,721 |
|
Deferred tax liabilities: |
|
|
|
|
|
|
||
Property and equipment |
|
|
(26,531 |
) |
|
|
(27,840 |
) |
Goodwill and intangibles |
|
|
(11,986 |
) |
|
|
(10,472 |
) |
Right-of-use assets |
|
|
(7,342 |
) |
|
|
(8,011 |
) |
Derivative conversion feature |
|
|
(26,913 |
) |
|
|
— |
|
Unrealized foreign exchange gain |
|
|
(872 |
) |
|
|
(396 |
) |
Total deferred tax liabilities |
|
|
(73,644 |
) |
|
|
(46,719 |
) |
Net deferred tax assets |
|
$ |
(3,998 |
) |
|
$ |
(3,998 |
) |
The realization of deferred tax assets is dependent on the Company’s ability to generate sufficient taxable income in future years in the associated jurisdiction to which the deferred tax assets relate. As of December 31, 2025, a valuation allowance of $246.4 million has been established against the deferred tax assets, as the Company has determined that it is currently not likely that these assets will be realized. During the year ended December 31, 2025, the valuation allowance decreased by $0.4 million, and during the years ended December 31, 2024 and 2023, the valuation allowance increased by $35.3 million and $43.6 million, respectively.
In determining the need for a valuation allowance, the Company considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance. Based on the review of all positive and negative evidence, including a three-year cumulative pretax loss, the Company determined that a full valuation allowance should be recorded against its deferred tax assets, with the exception of the net indefinite lived deferred tax liabilities and the Company’s Texas Temporary Credit for Business Loss Carryforwards.
The following table summarizes the changes to unrecognized tax benefits (in thousands):
|
|
Year ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Unrecognized tax benefit at the beginning of the year |
|
$ |
12,832 |
|
|
$ |
9,065 |
|
|
$ |
6,079 |
|
Increases in tax positions for prior years |
|
|
705 |
|
|
|
1,072 |
|
|
|
1,632 |
|
Increases in tax positions for current year relating to ongoing operations |
|
|
3,008 |
|
|
|
2,695 |
|
|
|
1,435 |
|
Decreases in tax positions as a result of a lapse of statute of limitations |
|
|
(308 |
) |
|
|
— |
|
|
|
(81 |
) |
Unrecognized tax benefits at the end of the year |
|
$ |
16,237 |
|
|
$ |
12,832 |
|
|
$ |
9,065 |
|
At December 31, 2025, 2024 and 2023, $15.0 million, $11.9 million and $8.6 million, respectively, of the Company’s total unrecognized tax benefits, if recognized, would impact the effective income tax rate.
In accordance with the disclosure requirements as described in ASC Topic 740, Income Taxes, the Company classifies uncertain tax positions as non-current income tax liabilities unless they are expected to be paid within one year. The Company recognizes interest and penalties related to income tax matters as a component of the income tax provision. As of December 31, 2025, 2024 and 2023, there were $0.1 million, $0.18 million and $0.1 million in accrued interest and penalties, respectively.
The Company and its subsidiaries are subject to federal income tax as well as income tax of multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to income tax examination by tax authorities in major jurisdictions for years prior to 2021. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses and tax credits were generated and carried forward and make adjustments up to the amount of the carryforwards. The Company is not currently under examination by the Internal Revenue Service, foreign or state and local tax authorities.
At December 31, 2025, the Company had federal, state, and foreign net operating loss carryforwards of $715.0 million, $565.7 million and $127.6 million, respectively. Federal and state net operating losses generated after December 31, 2017 of $577.6 million and $115.2 million, respectively, can be carried forward indefinitely. The remaining federal and state net operating losses begin expiring at various dates beginning in 2025 through 2044, while foreign net operating losses in France carryforward indefinitely. At December 31, 2025, the Company had federal and state research and development tax credit carryforwards of $12.7 million and $10.8 million, respectively. The federal research and development tax credits begin expiring in 2042 and the state research and development tax credits do not have an expiration date and may be carried forward indefinitely. At December 31, 2025, the Company also had interest expense carryovers of $100.5 million which can be carried forward indefinitely. Utilization of the net operating loss and tax credit carryforwards may become subject to annual limitations due to ownership change limitations that could occur in the future as provided by Section 382 and 383 of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”), as well as similar state provisions. These ownership changes may limit the amount of the net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company completed formal study through the year ended December 31, 2018 and determined ownership changes within the meaning of IRC Section 382 had occurred. The Company adjusted federal tax attribute carry forwards and deferred tax assets accordingly. The Company will make adjustments to the fully reserved attributes as further studies are completed.
On July 4, 2025, the One Big Beautiful Bill (“OBBBA”) was signed into law. The OBBBA includes a broad range of U.S. tax reform measures, including, among other provisions the immediate expensing of domestic research and development expenditures, 100% bonus depreciation for qualified assets and modifications to Section 163(j) interest expense limitations. In accordance with ASC 740, the Company has recognized the effects of the new tax law in the period of enactment. As the Company maintains a full valuation allowance on its U.S. deferred tax assets, the legislation does not have a material impact on its consolidated financial statements.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 24, 2026 | Showing above |
| 2017 | Mar 9, 2018 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.